ArticleInternational journal of molecular sciences2025
IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
Katarina Vuleta Nedic et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.